Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (54)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bianco, T.
Right arrow Articles by Dobrovic, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bianco, T.
Right arrow Articles by Dobrovic, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 21, No. 2, 147-151, February 2000
© 2000 Oxford University Press


Cancer Biology

Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer

Tina Bianco1,2, Georgia Chenevix-Trench5, David C.A. Walsh3, John E. Cooper4 and Alexander Dobrovic1,2,6

1 Department of Haematology–Oncology,
2 University of Adelaide Department of Medicine,
3 University of Adelaide Department of Surgery and
4 Department of Histopathology, The Queen Elizabeth Hospital, Woodville, SA 5011 and
5 The Queensland Institute of Medical Research and The University of Queensland, Royal Brisbane Hospital, Herston, QLD 4029, Australia

The role of BRCA1 in sporadic breast and ovarian cancers remains elusive. Direct involvement of BRCA1 in the development of breast and ovarian cancer is suggested by the finding that the BRCA1 promoter region CpG island is methylated in a proportion of breast and ovarian cancers. The aim of this study was to compare the incidence of BRCA1 promoter region methylation in tumours in which loss of BRCA1 has been shown to play a role in pathogenesis (breast and ovarian carcinomas) with the incidence in tumours in which BRCA1 is unlikely to play a role in pathogenesis. Promoter region hypermethylation was significantly more common (P < 0.008) in breast and ovarian cancer (6/38 tumours methylated) than in colon cancer (0/35 tumours methylated) or in leukaemias (0/19 samples methylated). The restriction of BRCA1 promoter region hypermethylation to breast and ovarian cancer is consistent with a pathogenetic role of BRCA1 promoter methylation in these tumours. We suggest that the rarity of observed BRCA1 mutations in sporadic breast and ovarian cancer is due to the greater likelihood of BRCA1 inactivation by non-mutational mechanisms such as methylation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. R. Bean, C. Ibarra Drendall, V. K. Goldenberg, J. C. Baker Jr., M. M. Troch, C. Paisie, L. G. Wilke, L. Yee, P. K. Marcom, B. F. Kimler, et al.
Hypermethylation of the Breast Cancer-Associated Gene 1 Promoter Does Not Predict Cytologic Atypia or Correlate with Surrogate End Points of Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 50 - 56.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D.-H. Shen, K. Y.-K. Chan, U.-S. Khoo, H. Y.-S. Ngan, W.-C. Xue, P.-M. Chiu, P. Ip, and A. N.-Y. Cheung
Epigenetic and genetic alterations of p33ING1b in ovarian cancer
Carcinogenesis, April 1, 2005; 26(4): 855 - 863.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. M. Hartikainen, H. Tuhkanen, V. Kataja, A. M. Dunning, A. Antoniou, P. Smith, A. Arffman, M. Pirskanen, D. F. Easton, M. Eskelinen, et al.
An Autosome-Wide Scan for Linkage Disequilibrium-Based Association in Sporadic Breast Cancer Cases in Eastern Finland: Three Candidate Regions Found
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 75 - 80.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
P. H. Lapchak, M. Melter, S. Pal, J. A. Flaxenburg, C. Geehan, M. H. Frank, D. Mukhopadhyay, and D. M. Briscoe
CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island
Am J Physiol Renal Physiol, September 1, 2004; 287(3): F512 - F520.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. Thakur, T. Nakamura, G. Calin, A. Russo, J. F. Tamburrino, M. Shimizu, G. Baldassarre, S. Battista, A. Fusco, R. P. Wassell, et al.
Regulation of BRCA1 Transcription by Specific Single-Stranded DNA Binding Factors
Mol. Cell. Biol., June 1, 2003; 23(11): 3774 - 3787.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. M. Baker, G. Wei, A. E. Schaffner, and M. C. Ostrowski
Ets-2 and Components of Mammalian SWI/SNF Form a Repressor Complex That Negatively Regulates the BRCA1 Promoter
J. Biol. Chem., May 9, 2003; 278(20): 17876 - 17884.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
G. Baldassarre, S. Battista, B. Belletti, S. Thakur, F. Pentimalli, F. Trapasso, M. Fedele, G. Pierantoni, C. M. Croce, and A. Fusco
Negative Regulation of BRCA1 Gene Expression by HMGA1 Proteins Accounts for the Reduced BRCA1 Protein Levels in Sporadic Breast Carcinoma
Mol. Cell. Biol., April 1, 2003; 23(7): 2225 - 2238.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Rathi, A. K. Virmani, J. O. Schorge, K. J. Elias, R. Maruyama, J. D. Minna, S. C. Mok, L. Girard, D. A. Fishman, and A. F. Gazdar
Methylation Profiles of Sporadic Ovarian Tumors and nonmalignant Ovaries from High-Risk Women
Clin. Cancer Res., November 1, 2002; 8(11): 3324 - 3331.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
C. Plass
Cancer epigenomics
Hum. Mol. Genet., October 1, 2002; 11(20): 2479 - 2488.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J. L. Hilton, J. P. Geisler, J. A. Rathe, M. A. Hattermann-Zogg, B. DeYoung, and R. E. Buller
Inactivation of BRCA1 and BRCA2 in Ovarian Cancer
J Natl Cancer Inst, September 18, 2002; 94(18): 1396 - 1406.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. A. Jazaeri, C. J. Yee, C. Sotiriou, K. R. Brantley, J. Boyd, and E. T. Liu
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
J Natl Cancer Inst, July 3, 2002; 94(13): 990 - 1000.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Sobczak and W. J. Krzyzosiak
Structural Determinants of BRCA1 Translational Regulation
J. Biol. Chem., May 3, 2002; 277(19): 17349 - 17358.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
J. Med. Genet., April 1, 2002; 39(4): 225 - 242.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L.-w. Tan, T. Bianco, and A. Dobrovic
Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer
Carcinogenesis, February 1, 2002; 23(2): 231 - 236.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. D. Jeffy, R. B. Chirnomas, E. J. Chen, J. M. Gudas, and D. F. Romagnolo
Activation of the Aromatic Hydrocarbon Receptor Pathway Is Not Sufficient for Transcriptional Repression of BRCA-1: Requirements for Metabolism of Benzo[a]pyrene to 7r,8t-Dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene
Cancer Res., January 1, 2002; 62(1): 113 - 121.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
J. F Costello and C. Plass
Methylation matters
J. Med. Genet., May 1, 2001; 38(5): 285 - 303.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman
A Gene Hypermethylation Profile of Human Cancer
Cancer Res., April 1, 2001; 61(8): 3225 - 3229.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. T. Hartsough, S. E. Clare, M. Mair, A. G. Elkahloun, D. Sgroi, C. K. Osborne, G. Clark, and P. S. Steeg
Elevation of Breast Carcinoma Nm23-H1 Metastasis Suppressor Gene Expression and Reduced Motility by DNA Methylation Inhibition
Cancer Res., March 1, 2001; 61(5): 2320 - 2327.
[Abstract] [Full Text]


Home page
Am. J. Pathol.Home page
G. Strathdee, K. Appleton, M. Illand, D. W. M. Millan, J. Sargent, J. Paul, and R. Brown
Primary Ovarian Carcinomas Display Multiple Methylator Phenotypes Involving Known Tumor Suppressor Genes
Am. J. Pathol., March 1, 2001; 158(3): 1121 - 1127.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. C. Rice, H. Ozcelik, P. Maxeiner, I. Andrulis, and B. W. Futscher
Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens
Carcinogenesis, September 1, 2000; 21(9): 1761 - 1765.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Hilakivi-Clarke
Estrogens, BRCA1, and Breast Cancer
Cancer Res., September 1, 2000; 60(18): 4993 - 5001.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.